Journal
ACS NANO
Volume 2, Issue 3, Pages 477-484Publisher
AMER CHEMICAL SOC
DOI: 10.1021/nn700400h
Keywords
iron oxide nanoparticles; phospholipid; contrast agents; drug delivery; magnetic resonance imaging; immunotargeted; MHC Class II
Categories
Funding
- NCI NIH HHS [5P01CA041078-14] Funding Source: Medline
- NIDDK NIH HHS [2 RO1 DK63567-03, R01 DK063567, 5 P30 DK063608-02] Funding Source: Medline
Ask authors/readers for more resources
We demonstrate the development and successful application of immunotargeted superparamagnetic iron oxide nanoparticles (ITSIONs), with in vivo magnetic resonance diagnostic and potential drug delivery capability for kidney disease. Further, the versatility of the conjugation chemistry presents an attractive route to the preparation of a range of biomolecule-nanoparticle conjugates. The ITSION contrast agent is a stable, biocompatible, targeted nanoparticle complex that combines a monodisperse iron oxide nanoparticle (ore with a functionalized phospholipid coating conjugated to antibodies that is capable of targeting normal cells expressing specific target antigens. The plasma half-life and R1 and R2 relaxivities suggest sufficient time for targeted binding while clearing from the system quick enough for detection of specific contrast enhancement. RT1 anti-MHC Class II antibodies were used to target the renal medulla of the rat, a section of the kidney in which MHC Class II, associated with inflammation, is specifically expressed. For in vivo resonance imaging, we compare phospholipid coated nanoparticles, nonspecific ITSIONs, and RT1 ITSIONs. Enhanced binding of the RTI ITSIONS indicates specificity for the renal medulla and thus potential for disease detection or drug delivery.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available